Sarcoidosis, Pulmonary Clinical Trial
— SopranosOfficial title:
A Pilot Study of Peripheral Airway Biopsy for the Diagnosis of Sarcoidosis
NCT number | NCT05759221 |
Other study ID # | 5279 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 20, 2022 |
Est. completion date | March 31, 2024 |
Verified date | April 2024 |
Source | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Airway involvement in sarcoidosis was demonstrated in a meaningful, albeit variable, proportion of patients through biopsy of the central, endoscopically visible airways. Ideally, biopsy of peripheral airways, nowadays possible with the introduction in the market of ultrathin bronchoscopes, might be associated with an increased diagnostic yield for the detection of granulomas.
Status | Completed |
Enrollment | 79 |
Est. completion date | March 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Necessity of a pathological confirmation of the clinical and radiological (CT) diagnosis of sarcoidosis. - Age >18 years - American Society of Anesthesiologists score 1-3. Exclusion Criteria: - Inability of unwillingness to consent - Steroid therapy (at least 1 week) in the 2 months preceding bronchoscopy. - Pregnancy. - Uncontrolled coagulopathy - Contraindication to the temporary interruption of anticoagulants or antiplatelet drugs, except aspirin. |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico Univeristario A. Gemelli IRCCS | Roma |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic yield of peripheral airway biopsy for the detection of granulomas | The diagnostic yield will be calculated on a per patient basis (number of patients in whom the pathological examination of peripheral airway biopsy shows non necrotizing granulomas/all the patients submitted to the sampling procedure). | 1 month | |
Secondary | Complication rate | Incidence of early complications | 1 day | |
Secondary | Diagnostic yield for the detection of endobronchial granulomas according to sex | The association between the sex (male vs female) and the diagnostic yield of peripheral airway biopsy will be assessed | 6 months | |
Secondary | Diagnostic yield for the detection of endobronchial granulomas according to the ethnicity | The association between the ethnicity (white versus other) and the diagnostic yield of peripheral airway biopsy will be assessed | 6 months | |
Secondary | Diagnostic yield for the detection of endobronchial granulomas according to the history of malignancy | The association between a history of malignancy (presence versus absence of any malignancy diagnosed within 5 years of the procedure) and the diagnostic yield of peripheral airway biopsy will be assessed | 6 months | |
Secondary | Diagnostic yield for the detection of endobronchial granulomas according to the sarcoidosis stage | The association between the sarcoidosis stage at CT (I vs II vs II vs IV) and the diagnostic yield of peripheral airway biopsy will be assessed | 6 months | |
Secondary | Diagnostic yield for the detection of endobronchial granulomas according to the presence of large airway mucosal abnormalities | The association between the presence of endoscopically visible large airway abnormalities and the diagnostic yield of peripheral airway biopsy will be assessed | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04020380 -
Azithromycin a Treatment for Pulmonary Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT03260556 -
Pirfenidone for Progressive Fibrotic Sarcoidosis
|
Phase 4 | |
Completed |
NCT03336736 -
The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
|
||
Completed |
NCT03140644 -
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
|
N/A | |
Completed |
NCT03793439 -
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
|
Phase 1 | |
Recruiting |
NCT04895111 -
Endobronchial Ultrasound Strain Elastography in Sarcoidosis
|
||
Not yet recruiting |
NCT05910554 -
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT05374447 -
Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy
|
N/A | |
Active, not recruiting |
NCT04314193 -
Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis
|
Phase 4 | |
Completed |
NCT03727451 -
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT05746039 -
Feasibility of Semaglutide in Advanced Lung Disease
|
Phase 1/Phase 2 | |
Completed |
NCT04803617 -
Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
|
||
Recruiting |
NCT03145922 -
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
|
||
Completed |
NCT00279708 -
Atorvastatin to Treat Pulmonary Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT05567133 -
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
|
||
Not yet recruiting |
NCT05291468 -
the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis
|
N/A | |
Completed |
NCT05311150 -
An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis
|
N/A | |
Completed |
NCT05811962 -
The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
|
||
Completed |
NCT03320070 -
Acthar Gel in Participants With Pulmonary Sarcoidosis
|
Phase 4 | |
Completed |
NCT03324503 -
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
|
N/A |